Literature DB >> 6718937

Treatment of antibiotic-associated pseudomembranous colitis.

J G Bartlett.   

Abstract

The experience of this laboratory with the treatment of Clostridium-induced colitis in experimental animals and in patients was reviewed. Optimal results in hamsters were achieved with the antibiotics vancomycin, metronidazole, and tetracycline. Cholestyramine was less effective. The outcome for animals given corticosteroids and Clostridium sordellii antitoxin systemically was not different from that for untreated control animals. The second facet of the study was a retrospective review of therapy in 272 patients with C. difficile-induced diarrhea or colitis. No specific therapy was given to 56 patients who had mild symptoms or were improving at the time the toxin was detected. The therapy most frequently used was oral vancomycin, which was given to 189 patients, including 100 with confirmed pseudomembranous colitis. The response rate was 97%, but 46 patients (24%) relapsed when treatment was discontinued. Response to cholestyramine was favorable in 12 of 19 patients. The results with metronidazole and bacitracin were uniformly good, although the experience was limited.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6718937     DOI: 10.1093/clinids/6.supplement_1.s235

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  27 in total

Review 1.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

Review 2.  Clostridium difficile infection in patients with HIV/AIDS.

Authors:  Paul J Collini; Ed Kuijper; David H Dockrell
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

3.  Incidence and significance of Clostridium difficile in hospitalized cancer patients.

Authors:  M Gérard; N Defresne; D Daneau; P Van der Auwera; M Delmée; A M Bourguignon; F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

Review 4.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

5.  Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro.

Authors:  A A Lima; D M Lyerly; T D Wilkins; D J Innes; R L Guerrant
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

6.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 7.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

8.  Intravenous teicoplanin does not prevent Clostridium difficile associated diarrhea.

Authors:  C Wenisch; E Etzersdorfer; S Breyer; W Graninger
Journal:  Clin Investig       Date:  1994-11

Review 9.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 10.  Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Krishna Rao; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.